Botulinum toxin and benign prostatic hyperplasia

doi:10.1016/j.ajur.2017.11.003

Asian Journal of Urology, 2018, 5 (1): 33-36 doi: 10.1016/j.ajur.2017.11.003

Review

Current Issue | Archive | Adv Search

Botulinum toxin and benign prostatic hyperplasia

Guat Ng Lay

Department of Urology, Singapore General Hospital, Singapore

Abstract
Related Citation (15)

Download:

HTML

PDF (238KB)
Export: BibTeX | EndNote (RIS)

Abstract

Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms. However, with review of animal studies and unexplained exaggerated effect of the placebo arms of the two RCTs, together with recent data of sustained benefits after 18 months of treatment, the place of botulinum toxin in the BPH field is probably still present.

Key words： Benign prostatic hyperplasia Botulinum toxin Bladder outlet obstruction

Received: 21 February 2017 Published: 07 March 2018

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Guat Ng Lay

TRENDMD:

Cite this article:

Guat Ng Lay. Botulinum toxin and benign prostatic hyperplasia[J]. Asian Journal of Urology, 2018, 5(1): 33-36.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2017.11.003 OR http://www.ajurology.com/EN/Y2018/V5/I1/33

[1]	Marinese D, Patel R, Walden PD . Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate, 2003;54: 230-7.
[2]	Simpson LL . Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol , 1986;26: 427-53.
[3]	Aoki KR . Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology, 2005;26: 785-93.
[4]	Chuang YC, Giannantoni A, Chancellor MB . The potential and promise of using botulinum toxin in the prostate gland. BJU Int, 2006;98: 28-32.
[5]	Lin AT, Yang AH, Chen KK . Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol, 2007;52: 582-9.
[6]	Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A . Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology, 2003;62: 259-64.
[7]	Kuo HC . Prostate botulinum A toxin injectionean alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology, 2005;65: 670-4.
[8]	Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB . Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology, 2005;66: 775-9.
[9]	Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB . Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int, 2006;98: 1033-7.
[10]	Sacco E, Bientinesi R, Marangi F, Totaro A , D’Addessi A, Racioppi M, et al. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic onabotulinumtoxin A: 3-month results of a prospective single-armed cohort study. BJU Int, 2012;110: E837-44.
[11]	Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G . Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology, 2009;73: 90-4.
[12]	Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P , et al. Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol, 2008;53: 153-9.
[13]	Hsu YC, Wang HJ, Chuang YC . Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia-a spotlight in reality. Toxins Basel, 2016;8: 126.
[14]	Kuo YC, Kuo HC . Botulinum toxin injection for lower urinary tract dysfunction. Int J Urol, 2013;20: 40-55.
[15]	Shim SR, Cho YJ, Shin IS, Kim JH . Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol, 2016; 48: 19-30.
[16]	Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D, et al . A randomized double-blind placebocontrolled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol, 2013;63: 496-503.
[17]	McVary KT, Roehrborn CG, Chartier-Kastler E, Efros M, Bugarin D, Chen R, et al . A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol, 2014;192: 150-6.
[18]	Robert GY, Descazeaud A, Benard A, Delongchamps NB . A randomised clinical trial comparing prostatic injection of botulinum neurotoxin type A (Botox_) to optimized medical therapy in the treatment of LUTS related to BPH: the PROTOX study. Eur Urol Suppl, 2015;14. e685-e685a.
[19]	Delongchamps NB, Descazeaud A, Benard A, Azzouzi R, Saussine C , De La Taille A, et al. A randomized clinical trial comparing prostatic injection of botulinum neurotoxin type A (Botox_) to optimized medical therapy in patients with BPHrelated LUTS: end-of-study results of the PROTOX trial. Eur Urol Suppl, 2016;15. e1079-e1079a.